U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06911203) titled 'A Study of BGM0504 in Participants With Obesity' on April 03.
Brief Summary: To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
Study Start Date: April 08
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: BGM0504
Administered SC
DRUG: Tirzepatide
Administered SC
Recruitment Status: RECRUITING
Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....